Regentis Biomaterials Ltd. (NYSE American: RGNT) is developing GelrinC, an acellular hydrogel implant designed to shift knee cartilage treatment from symptom management toward early structural repair. The company, which is covered by Regentis Biomaterials (NYSE American: RGNT), reported promising clinical data and outlined plans for U.S. regulatory approval.
GelrinC is engineered to gradually resorb as surrounding cells regenerate hyaline-like cartilage, avoiding the need for cell harvesting and a second surgery. This contrasts with microfracture, a common procedure that can produce less-durable fibrocartilage. In a Phase II study, Regentis reported roughly 100% greater KOOS improvement versus microfracture at 24 months, along with a mean MOCART score of 88.8/100, indicating strong structural repair.
The company has already received CE Mark approval in Europe and is conducting a pivotal U.S. trial targeting completion around year-end 2026. Longer-term development programs are aimed at smaller-joint defects and moderate osteoarthritis. Regentis is positioning its technology around the broader orthopedic trend toward earlier intervention and durable tissue preservation rather than waiting for disease progression.
GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. The company estimates that GelrinC addresses a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
To view the full article, visit https://ibn.fm/DjPC4. The latest news and updates relating to RGNT are available in the company's newsroom at https//ibn.fm/RGNT.
This content has been disseminated on behalf of Regentis Biomaterials Ltd. as part of a paid investor awareness and marketing engagement. BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, published the original announcement. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries.
For more information, please visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
